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Abstract
Lapses in self-care are commonly cited as a major cause of poor outcomes in persons with heart failure (HF).
Not surprisingly, self-care is assumed to be central to improving health outcomes in this patient population.
Empirically, however, this assumption is not well supported, and mechanistically, relationships between self-
care and outcomes in HF have not yet been described. In this review, it is proposed that effective self-care
maintenance (adherence) and self-care management (symptom evaluation and management) practices are
complementary to optimal medical management in delaying HF progression and improving health outcomes
in this population. Potential mechanisms through which effective HF self-care practices are complementary to
pharmacological therapy in improving outcomes include (a) facilitating partial blockade and partial
deactivation of deleterious neurohormones, (b) limiting inflammatory processes, (c) decreasing the need for
administration of detrimental pharmacological agents, and (d) minimizing myocardial hibernation. Because
these mechanisms are hypothetical, research findings are required to establish their validity. Several strategic
research questions are proposed.
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Abstract
Lapses in self-care are commonly cited as a major cause of poor outcomes in persons with heart
failure (HF). Not surprisingly, self-care is assumed to be central to improving health outcomes in
this patient population. Empirically, however, this assumption is not well supported, and
mechanistically, relationships between self-care and outcomes in HF have not yet been described.
In this review, it is proposed that effective self-care maintenance (adherence) and self-care
management (symptom evaluation and management) practices are complementary to optimal
medical management in delaying HF progression and improving health outcomes in this population.
Potential mechanisms through which effective HF self-care practices are complementary to
pharmacological therapy in improving outcomes include; a) facilitating partial blockade and partial
deactivation of deleterious neurohomones, b) limiting inflammatory processes, c) decreasing the
need for administration of detrimental pharmacological agents, and d) minimizing myocardial
hibernation. As these mechanisms are hypothetical, research findings are required to establish their
validity. Several strategic research questions are proposed.
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Introduction
Poor outcomes in heart failure (HF) are commonly attributed to insufficient self-care practices.
1–3 Likewise, it is a commonly held view that effective self-care is central to improving health
outcomes in the HF population, ostensibly because persons with HF are responsible for the
majority of their own care.4 Currently, there is inadequate evidence to support the assumption
that better HF self-care translates into better outcomes. Similarly, assumed mechanisms
through which HF self-care may influence health outcomes remain untested.
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The purpose of this review is to present hypothetical mechanisms through which self-care may
influence health outcomes in persons with HF. In general, we propose that effective self-care
practices are cardioprotective. Specifically, it is proposed that persons who are more engaged
in HF self-care may have better health outcomes due to: a) achieving and maintaining effective
neurohormonal blockade and partial deactivation, b) minimizing inflammation, c) avoiding the
need for deleterious pharmacological therapy, and d) limiting myocardial hibernation. In this
review, a contemporary definition of HF self-care is provided. Key elements of these four
hypothetical mechanisms are then reviewed in brief. This review concludes with clinical
practice and research implications of these potential mechanisms.
Heart Failure Self-Care: Contemporary Perspective
HF self-care is an active process involving critical behaviors that help maintain physiologic
homeostasis and prevent acute exacerbations (self-care maintenance). HF self-care also
involves decision-making in which patients engage and actions they take to effectively evaluate
and manage symptoms when they occur (self-care management).5 (Figure 1)
Heart Failure Self-Care Maintenance
Self-care maintenance behaviors reflect the degree to which a HF patient follows health actions
set forth by and in agreement with a healthcare provider.6 This important aspect of HF self-
care is commonly referred to as treatment adherence. Self-care maintenance behaviors include
routine daily practices. HF patients who practice effective self-care maintenance are adherent
to prescribed hormone blockers and diuretics, dietary sodium restriction, measurement of daily
weight, and symptom surveillance.7 Further, patients who practice effective self-care
maintenance exercise regularly, avoid potentially harmful medications like non-steroidal anti-
inflammatory drugs, and participate in several other health-seeking behaviors like maintaining
scheduled immunizations. In contrast, patients who practice poor self-care maintenance may
go for periods of time without taking prescribed medications that help suppress deleterious
hormones activated during HF. In addition, poor self-care maintenance can be manifested by
non-adherence to daily treatment activities including dietary sodium restriction, and symptom
surveillance.
Heart Failure Self-Care Management
Self-care management refers to a patient’s ability to quickly recognize HF symptoms when
they occur, engage in a management strategy to ameliorate symptoms, and judge the
effectiveness of their self-directed treatment strategies.8 In the event of a sign of fluid excess
or subtle congestive symptom, patients who practice effective self-care management quickly
recognize the change and act to ameliorate symptoms by limiting fluid or sodium intake, or
taking additional doses of low-dose diuretics as a treatment strategy. Persons who practice
effective self-care management are able to judge the effectiveness of self-engaged
treatments7 and determine if they must return to a state of surveillance or involve healthcare
practitioners in the management of HF symptoms.9 On the contrary, patients who practice poor
self-care management are not likely to quickly recognize signs and symptoms as manifestations
of their chronic HF, and are not likely to take appropriate action when congestive symptoms
occur. Further, patients who practice poor self-care management are unlikely to be able to judge
the effectiveness of their self-engaged treatments.
Potential Mechanisms Through Which Self-Care Influences Health Outcomes
Heart Failure Self-Care and Cardioprotection
In persons with HF, cardioprotective strategies aim to delay the progression of cardiomyocyte
death and untoward outcomes, such as advanced ventricular dysfunction or frequent episodes
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of clinical congestion that lead to re-hospitalization and death.10 In the broadest sense, effective
self-care is complementary to optimal medical management in delaying HF progression and
poor health outcomes and in this way is cardioprotective. Although four hypothetical
mechanisms by which HF self-care may influence outcomes are presented individually, it is
more likely that effective self-care practices influence multiple if not all four means of
cardioprotection concurrently.
Potential Mechanism I: Neurohormonal Blockade and Partial Deactivation
According to a widely held theory of the natural progression of HF,11 hormones produced in
response to HF cause hemodynamic congestion. Congestion may leave an indelible mark by
overloading the heart and further impairing cardiac hemodynamics.12 Unrecognized and
untreated congestion eventually leads to burdensome and disabling HF symptoms,13
progressive cardiocirculatory deterioration, and eventually death. Effective self-care
maintenance and management may help interrupt and delay this progression of HF.
Predominantly in response to changes in arterial pressure and filling the sympathetic nervous
system (SNS) mounts a rapid, robust and complex response that is largely mediated by
norepinephrine (NE). The initial cardiovascular effects of SNS activation include positive
chronotropism, dromotropism, inotropism and lusitropism, as well as venous and arteriolar
vasoconstriction.14, 15 These cardiocirculatory adaptations initially help restore cardiac output
and mean arterial pressure. Renin-angiotensin-aldosterone system (RAAS) activation,
triggered by decreased renal pressure16 and SNS stimulation,17 is also initially compensatory
in restoring mean arterial pressure. As an example, angiotensin II (ANG-II), a RAAS mediator,
is a potent vasoconstrictor that also stimulates aldosterone-mediated water and sodium
conservation,18 which in combination restores blood volume, cardiac output and mean arterial
pressure. Chronic SNS and RAAS activation, however, lead to increased afterload,
hemodynamic and clinical congestion,19 increased myocardial oxygen demand, intracellular
calcium toxicity, as well as proliferative14 and pro-inflammatory effects.20
Effective self-care maintenance includes taking neurohormonal blockers, such as β-adrenergic
blockers and angiotensin converting enzyme (ACE) inhibitors regularly as prescribed. The
essential step of medication adherence helps minimize the cardiocirculatory burden of elevated
levels of NE and ANG-II and has numerous and well established health outcome benefits.
Maintaining optimal sodium and water balance also may minimize activation of certain
neurohormonal systems. Although a source of unresolved controversy,21 adhering to dietary
fluid and sodium restriction are thought to be effective in maintaining optimal sodium and
water balance and minimizing the risk of congestive episodes. This assumption is based on
evidence that lapses in dietary restriction increase the risk of HF readmission and mortality,
22, 23 and the fundamental principle that neurohormonal activation limits the body’s ability
to excrete ingested sodium and water.24
Effective self-care management is also essential to limiting the burden of neurohormones and
partially deactivating neurohormonal systems. Engagement in symptom management is
dependent on sensing and interpreting symptoms when they occur, which can be difficult for
HF patients.25 Persons who are able to recognize HF symptoms early, however, are likely to
engage in self-initiated treatment strategies that are relatively less aggressive and to avoid long
delays in treatment-seeking that have been identified in this patient population.26 For example,
persons with HF may be able to manage their symptoms by merely restricting fluid or sodium
intake or to manage their congestion with comparatively low-dose diuretics. Decreased
congestion, as a result of low-dose diuretics and limited sodium and water intake, helps
optimize blood volume and cardiac hemodynamics and thereby deactivates several
neurohomonal systems including SNS and RAAS. At the same time, such small, patient-
managed adjustments decrease the risk of reactive increases in neurohormonal activation that
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can occur with greater changes in sodium intake27 and in response to high-dose diuretics.28
Further, managing fluid and sodium intake may improve congestion and the effectiveness of
β-blocking agents.29 That is, β-blocking agents are thought to have greater cardioprotective
effects in the absence of clinical congestion.30 Thus, patients who effectively manage episodes
of congestion may benefit from improved neurohormonal blocker efficacy.
Generalized neurohormonal activation, involving the secretion of additional hormones like
arginine vasopressin (AVP) and endothelin 1 (ET-1), occurs late in the progression of HF.12
AVP is secreted in response to arterial underfilling,31 and causes vasoconstriction, water
conservation, and enhanced catecholamine responsiveness, all which contribute to congestion.
ET-1 is produced within endothelial cells in response to various stimuli including shear stress,
hypoxia, and other circulating hormones such as ANG-II and AVP.32 ET-1 causes potent and
sustained vasoconstriction,33 as well as positive chronotropism and inotropism in contractile
cells.32 While pharmaceutical agents that block AVP and ET-1 may be prescribed in addition
to standard therapy, the secretion of these hormones also can be minimized by suppression of
SNS and RAAS and optimization of cardiac hemodynamics with effective self-care
management practices. As an example, prompt self-management of congestion may improve
cardiac hemodynamics enough to deactivate non-osmotic AVP secretion. In addition, partial
SNS suppression by the prompt treatment of subtle HF symptoms and adherence to β-
adrenergic blockers limits ET-1 secretion.34
Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted from
cardiomyocytes in response to wall stretch.35 Secretion of both natriuretic peptides is also
stimulated by several circulating substances including NE, ANG-II, AVP, ET-1 and numerous
inflammatory cytokines.35 The natriuretic peptides have beneficial cardioprotective effects,
including diuresis, natriuresis, cardiomyocyte relaxation and vasodilatation.35 These
cardioprotective effects, however, are often opposed by concomitant increases in
neurohormones, such as NE and ANG-II, with antagonistic cardiocirculatory effects.24, 27
Thus, the full cardioprotective benefits of the natriuretic peptides are only achieved when the
effects of other neurohormonal systems (e.g. SNS & RAAS) are partially blocked
pharmacologically. In this manner, persons who are adequately engaged in effective self-care
maintenance practices are more likely to benefit from the action of endogenous ANP and BNP,
as the effects of cardiostimulatory and vasoconstrictive hormones are suppressed. Benefits of
another cardioprotective hormone, bradykinin, can also be enhanced by adherence to ACE
inhibitors.36
In summary, (Figure 2) persons who engage in effective HF self-care practices are more likely
to maintain fluid volume balance and avoid clinical congestion. They are able to partially block
the detrimental neurohormones of HF, such as NE, ANG-II, AVP and ET-1, and at the same
time partially deactivate these neurohormonal systems. Persons who are engaged in effective
self-care practices are able to have a favorable balance between natriuretic peptides and
disadvantageous hormones and to benefit from the augmented effect of other endogenous
cardioprotective hormones like bradykinin. In addition, because they are more likely to manage
episodes of congestion, persons with HF who are engaged in effective self-care are able to
garner the benefit of enhanced pharmacological effectiveness.
Potential Mechanism II: Minimizing Inflammation
According to the “cytokine hypothesis”,37 several inflammatory mediators are expressed in
response to HF, and both modulate and contribute to HF pathogenesis. Pro-inflammatory
cytokines are thought to promote ventricular remodeling by inducing ventricular hypertrophy,
fibrosis and apoptosis.38 Several potential mechanisms through which inflammatory mediators
are activated in HF have been proposed.
Lee et al. Page 4
J Cardiovasc Nurs. Author manuscript; available in PMC 2010 June 7.
Laminar shear stress exerts an anti-inflammatory effect in healthy humans.39 In contrast, when
the endothelium is disrupted by hemodynamic stress, leukocyte and platelet adhesion and
expression of pro-inflammatory cytokines like monocyte chemoattractant protein-1 (MCP-1)
is triggered.40 In addition, direct hemodynamic stretch triggers myocardial production of the
pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6).41
TNFα is thought to cause profound contractile dysfunction and induction of apoptosis.42
Chronic elevation of IL-6 leads to ventricular hypertrophy43 and negative inotropism.44 It
also is hypothesized that IL-6 activation in HF inhibits the expression of cardioprotective
peptides like ANP.43 Cytokines have been implicated in the induction of reactive oxygen
species, which contribute to the progression of HF by decreasing contractile force and inducing
apoptosis.45 Accordingly, actions that ameliorate hemodynamic stress and mechanical stretch
are likely to limit the expression and secretion of inflammatory mediators.
Maintaining volume homeostasis and optimal cardiac hemodynamics decreases the likelihood
of mechanical stress and stretch. In patients with HF, mechanical stress and stretch are
controlled through the early and effective management of episodes of congestion. That is, HF
patients who quickly recognize and treat HF symptoms are likely to ameliorate episodes of
congestion that contribute to mechanical stress and stretch and subsequent expression of pro-
inflammatory mediators. Adherence to neurohormonal blockers may also limit the impact of
inflammatory mediators in persons with HF. For example, there is evidence that β-blocking
agents decrease levels of TNFα and IL-6 in patients with cardiomyopathy.46 In addition,
improvement in ejection fraction and functional capacity after initiation of β-blocking agents
in patients with HF is highly correlated with a concomitant decrease in plasma IL-6.47
Infection also may lead to inflammation in patients with HF. Seemingly simple health
maintenance behaviors such as hand washing, preventative dental health, and maintenance of
scheduled immunizations have the potential to limit inflammation and the associated
detrimental cardiac effects. As an example, poor dental health is linked to development of
cardiovascular disease and mortality.48 Further, the risk of hospitalization for HF is increased
during influenza season,49 a risk that can be minimized by taking influenza vaccine.50 As an
additional source of infection, bacterial endotoxins translocate from the gut to the blood stream
during episodes of congestion, a possible cause of elevated levels of inflammatory markers in
patients with HF.51, 52 Symptom monitoring and management of episodes of congestion appear
to be critical. That is, it is conceivable that patients who are more vigilant in monitoring for
subtle congestive signs and symptoms and who engage in effective management strategies are
more likely to minimize bacterial translocation that occurs during episodes of congestion.
Tissue ischemia can also induce pro-inflammatory cytokine production. Intracellular stress
signals respond to hypoxia and subsequent tissue injury, inducing expression of IL-6,41
TNFα, and MCP-1.40 One way of improving oxygen delivery is routine exercise. Although the
source of ongoing debate, there is evidence that exercise increases anaerobic threshold,53 and
increases peak oxygen uptake in persons with HF,54 and increases coronary flow reserve in
persons with coronary artery disease.55 Thus exercise may be one way in which persons with
HF can optimize tissue oxygen delivery and minimize ischemia. Adhering to β-blockers also
aids in reducing myocardial ischemia, as these agents decrease myocardial oxygen demand.
56 Moreover, managing episodes of congestion is likely to decrease wall tension that decreases
subendocardial perfusion and limits optimal cardiac hemodynamics. In fact, the majority of
subendocardial perfusion occurs during diastole. If end-diastolic volumes and pressures are
high then wall tension is also high, limiting blood flow to the myocardial muscle.57 Patients
who are able to recognize early symptoms of congestion and engage in effective management
strategies are more likely to optimize diastolic filling pressures and limit the potential ischemic
insult from such congestive episodes.
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In summary, through effective self-care maintenance and management behaviors, persons with
HF may limit active inflammatory processes and cytokine elevations that are linked to poor
outcomes in HF. Potential mechanisms include the reduction of infectious processes, like
influenza or dental caries, and the prevention or management of congestion that may foster gut
bacterial translocation or myocardial mechanical stress and ischemia in persons with HF.
Potential Mechanism III: Avoiding the Need for Deleterious Pharmacology
When the management of HF symptoms is refractory to self-care, neurohormonal activation
and inflammation severely impair cardiac hemodynamics and induce further myocardial injury,
19 often necessitating emergency department and/or hospital admission. Managing acute
decompensated HF (also referred to as acute HF syndrome58) solely under the hemodynamic
paradigm requires high-dose diuretics, inodilators (agents with both positive inotropic and
vasodilator effects) and the withdrawal of β-blockers. Effective self-care maintenance and
management may prevent acute decompensated HF and the need for complex and aggressive
management that is potentially deleterious.
Once effective neurohormonal blockade is achieved, there is strong advocacy for the
management of HF with minimal diuretic dosing or without diuretics.28 This is due in part to
a growing body of evidence that the use of diuretics is associated with poor outcomes in persons
with HF.59–62 Potential reasons for hazards associated with diuretics include resultant
electrolyte disturbances, excessive neurohormonal activation, hypovolemia and renal
impairment.28 Routine use of inodilator agents in the treatment of persons with acute or chronic
HF may also result in poor outcomes.63–66 Inodilators, like certain exogenous catecholamines
and phosphodiesterase inhibitors, induce tachycardia, ischemia, hypotension and necrosis, and
increase ectopy.63 Although they may transiently improve function, the risks of this class of
drugs appear to outweigh their long-term benefits. In addition, during hospitalization for acute
episodes of congestion, β-blocking agents are often reduced or temporarily discontinued.
Reduction of β-blocker dose or cessation, however, is associated with an increased risk of
mortality.67
Strict adherence to neurohormonal blockers, fluid and sodium intake reduction/restriction and
preventative health measures are key aspects of HF self-care maintenance that may help prevent
the evolution of acute decompensated HF. Symptom monitoring is a particularly important
aspect of self-care maintenance that facilitates early recognition and actions that effectively
ameliorate symptoms when they occur. Persons who practice effective symptom monitoring
may recognize early satiety or fatigue or clothes feeling tight as evidence of congestion
requiring treatment. On the contrary, if subtle or even hallmark signs and symptoms are missed
or not considered symptoms of HF, congestive episodes are likely to progress to acute
decompensated HF where self-initiated treatments may be less effective.
Self-care management of HF symptoms also prevents acute decompensated HF and the need
for aggressive management. HF patients experience daily fluctuations in HF symptoms,68
making it difficult to interpret symptom severity and even the presence of symptoms with an
insidious onset.69 Persons who are able to quickly recognize worsening HF symptoms,
however, are more likely to engage in timely and effective self-care management strategies
that ameliorate symptoms by means that are much less aggressive than high-dose diuretic or
inodilator therapy. Further, HF patients who are able to judge the effectiveness of their self-
initiated treatment strategies are more likely to take appropriate action in follow-up of episodes
of congestion. Namely, persons engaged in effective self-care management are able to assess
the need for continued or alternative symptom treatment, engagement of healthcare providers
in their symptom management, and/or continued symptom surveillance.
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Potential Mechanism IV: Myocardial Hibernation
Myocardial hibernation is the phenomenon of chronic and reversible ventricular dysfunction
due to inadequate coronary perfusion.70 Unlike complete coronary artery occlusion, coronary
hypoperfusion that causes myocardial hibernation is not severe enough to induce necrosis or
apoptosis. Rather, ischemic insults reduce inotropic force of segments of the ventricle.70 The
pathogenesis of hibernating myocardium is largely unclear. Structural alterations, including
contractile protein depletion and fibrosis and metabolic derangements, as well as decreased
coronary flow reserve71 and resting myocardial perfusion72 have been previously cited as
potential contributors to myocardial hibernation.
Hibernating myocardium is problematic for patients with HF, as these regions of the ventricle
are prone to repeated episodes of ischemia and may progress to necrosis or apoptosis.71
Repeated ischemic insults can be due to progressive stenosis or wall tension that limits
subendocardial blood flow. Most importantly, hibernating myocardium represents viable
myocardial tissue, the function of which may be improved by ameliorating the mismatch
between coronary flow and function. Coronary revascularization has certain utility in
improving the function of hibernating myocardium. Maintaining blood volume homeostasis
by adhering to prescribed dietary restrictions and taking HF medications as prescribed may
reduce the frequency and duration of episodes of increased wall tension and ischemia. Rapid
self-management of congestive symptoms also has implications in improving myocardial
viability. That is, patients who practice effective self-care management are more likely to avoid
prolonged episodes of increased transmural pressure and myocardial ischemia that trigger the
progression of compensated myocardium into hibernation, or from hibernating myocardium
to necrosis/apoptosis.
One mechanism through which β-adrenergic blockers are thought to improve myocardial
function in HF is through improvements in the balance of myocardial oxygen supply and
demand. In support of this hypothesis, patients with known hibernating myocardium have a
greater increase in ejection fraction after the addition of a β-blocking agent than HF patients
without hibernating myocardium.73 It is thought that this improvement in contractile function
may be due, at least in part, to improved function of areas of the myocardium that were
hibernating. Accordingly, prescription of β-blockers was proposed as a complementary or
alternative therapy to revascularization in patients with hibernating myocardium.73 Adherence
to β-blockers may well improve viability of hibernating myocardium. Moreover, routine
exercise may also have important implications, particularly if the increased coronary flow
reserve found in persons with coronary artery disease who exercise55 also exists is persons
with non-ischemic HF.
Implications for Clinical Practice and Research
Teaching and fostering effective self-care practices in persons with HF is assumed to be
evidence-based. To date, however, there are limited data to support this claim. As described,
there are several possible mechanisms through which patients with HF may be able to impact
their own health through effective self-care practices. Helping patients with HF learn how to
master the maintenance of their health and management of HF symptoms remains central to
multidisciplinary HF disease management programs. Improvements in self-care practices may
be complementary to optimal pharmacological treatment of HF, and may be the link to
improving patient outcomes that has been missing for decades in this population.
As the majority of research regarding HF self-care has aimed to identify factors that influence
HF self-care ability, there are several implicit programs of research suggested. Specifically,
the link between HF self-care behavior (both self-care maintenance and self-care management)
and physiological surrogates and clinical outcomes has yet to be made. Accordingly, there are
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five general research questions associated with this aspect of HF self-care research (Table 1).
First, is there an association between level of engagement in self-care and indices of
neurohormonal activation in persons with HF? Second, is there an association between level
of engagement in self-care and indices of inflammation? Third, is there a link between effective
self-care and the decreased need for acute pharmacological agents with controversial or
deleterious effects? Fourth, is there an association between HF self-care and myocardial
viability? Finally, is there a direct association between self-care and health outcomes, like HF
readmission and mortality?
Conclusion
It is a commonly held view that self-care is a major contributor to optimal HF management.
This manuscript explored several hypothetical mechanisms through which HF self care may
influence outcomes. In general, HF self-care is thought to be cardioprotective, and
complementary to optimal medical management in the improvement of health outcomes.
Specifically, it is thought that effective HF self-care practices facilitate partial neurohormonal
blockade and deactivation, limit inflammatory processes, minimize the need for
disadvantageous pharmacological therapy, and minimize myocardial hibernation. These
hypothetical mechanisms need to be validated by the results of ongoing and future clinical
research.
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Figure 1. Contemporary Model of Heart Failure Self-Care
Heart Self-care maintenance in persons with heart failure includes routine daily practices, such
as taking prescribed medications, maintaining fluid volume by limiting dietary sodium intake,
and participating in health seeking behaviors like exercise. Self-care management in persons
with heart failure includes symptom recognition and evaluation, engagement in strategies to
ameliorate symptoms, and judgment of the effectiveness of self-directed treatment strategies.
Source: Author
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Figure 2. Hypothetical Mechanisms Through Which Heart Failure Self-Care Influences Health
Outcomes
Effective self-care behaviors are cardioprotective, potentially delaying HF progression and
improving outcomes in persons with HF. It is proposed that effective self-care practices are
complementary to pharmacological therapies in improving outcomes by promoting
neurohormonal blockade and deactivation, limiting inflammatory processes, decreasing the
likelihood of detrimental changes to pharmacological management, and limiting the extent of
myocardial hibernation. See text for details. Abbreviations: ANG-II = angiotensin II, AVP =
arginine vasopressin, BK = bradykinin, ET-1 = endothelin, HF = heart failure, IL-6 =
interleukin 6, Meds. = medications, MCP-1 = monocyte chemoattractant protein 1, NE =
norepinephrine, NP = natriuretic peptides, ROS = reactive oxygen species, TNFα = tumor
necrosis factor alpha. Source: Author
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Table 1
Research Priorities. In order to begin validating the hypothetical mechanism described herein, several research
questions are proposed.
Research Questions
Neurohormonal blockade and deactivation:
    1) Are higher levels of engagement in self-care behaviors associated with lower
    plasma levels of NE, ANG-II, AVP, ET-1, ANP or BNP?
Inflammation:
    1) Are higher levels of engagement in self-care behaviors associated with lower
    plasma levels of TNFα, IL-6, CRP, or decreased incidence of systemic infection?
Need for aggressive and disadvantageous pharmacological therapy:
    1) Are higher levels of engagement in self-care behaviors associated with decreased
    high-dose diuretic or inodilator use, or less neurohormonal blocker discontinuation?
Myocardial hibernation:
    1) Do patients who are more engaged in self-care behaviors have less hibernating
    myocardium, or have greater improvements in EF after the initiation of β-blockade?
Abbreviations: β-blockade = beta adrenergic blockade, ANP = atrial natriuretic peptide, ANG-II = angiotensin II, AVP = arginine vasopressin, BNP
= B-type natriuretic peptide, CRP = C-reactive protein, EF = ejection fraction, ET-1 = endothelin 1, IL-6 = interleukin 6, TNFα = tumor necrosis
factor alpha.
Source: Author
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